CUMBERLAND

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2024 FINANCIAL RESULTS

Retrieved on: 
火曜日, 4月 30, 2024
Pain, FDA, Omeprazole, Fungal infection, Gastroenterology, Lactulose, PIN, Skin, Clarithromycin, Nausea, Hyponatremia, Infection, Paracetamol, Amoxicillin, Cardiomyopathy, Duchenne muscular dystrophy, Helicobacter pylori, Vomiting, Patient, Idiopathic pulmonary fibrosis, Constipation, Granisetron, Multimedia, Health, Acetylcysteine, Fever, Ibuprofen

NASHVILLE, Tenn., April 30, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2024 financial results and provide a company update after the market closes on Tuesday, May 7, 2024.

Key Points: 
  • NASHVILLE, Tenn., April 30, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2024 financial results and provide a company update after the market closes on Tuesday, May 7, 2024.
  • A conference call will be held on May 7 at 4:30 p.m. Eastern Time to discuss the results.
  • Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them.
  • Cumberland Pharmaceuticals is a specialty pharmaceutical company focused on providing unique products that improve patient care.

RS BioTherapeutics Adds Jane Wright-Mitchell, Pharm.D., J.D. to Business Advisory Board

Retrieved on: 
木曜日, 4月 25, 2024
Corporation, University, Clemson University, Pharmacy, General counsel, Champaign–Urbana metropolitan area, Biology, Business, CBD, Principal, Pharming, Patent, Pharmaceutical industry

to the RS BioTherapeutics Business Advisory Board.

Key Points: 
  • to the RS BioTherapeutics Business Advisory Board.
  • As a member of the Business Advisory Board, Ms. Wright-Mitchell will also serve as fractional General Counsel and Compliance Advisor for RS BioTherapeutics.
  • Commenting on the addition of Ms. Wright-Mitchell to the Business Advisory Board, Dean Hart, Chief Executive Officer of RS BioTherapeutics said, “I was fortunate to work with Jane while we were both at AcelRx and am thrilled to have her join our Business Advisory Board.
  • She is registered to practice before the United States Patent and Trademark Office as well as a licensed pharmacist (Illinois).

RS BioTherapeutics Selected for Presentation at American Thoracic Society’s 2024 Respiratory Innovation Summit

Retrieved on: 
月曜日, 3月 18, 2024
ATS, Science, Medicine, American Thoracic Society, Chronic obstructive pulmonary disease, Death, Idiopathic pulmonary fibrosis, IPF, COPD, Idiopathic disease, Government

CUMBERLAND, Md., March 18, 2024 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to develop life-changing medicines for the millions of people suffering from diseases characterized by pulmonary inflammation, is pleased to announce that its submission has been selected for a poster presentation at the 2024 Respiratory Innovation Summit hosted by the American Thoracic Society (ATS).

Key Points: 
  • CUMBERLAND, Md., March 18, 2024 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to develop life-changing medicines for the millions of people suffering from diseases characterized by pulmonary inflammation, is pleased to announce that its submission has been selected for a poster presentation at the 2024 Respiratory Innovation Summit hosted by the American Thoracic Society (ATS).
  • The summit will be held at the Manchester Grand Hyatt in San Diego, California on Friday, May 17 and Saturday, May 18.
  • The ATS 2024 Respiratory Innovation Summit will unite the innovators, investors, clinicians, and advocacy groups who are leading the charge to create powerful new treatments for deadly and crippling diseases of the lungs and airways.
  • Commenting on RS BioTherapeutics’ selection, the company’s Chief Medical Officer, Dr. Michelle L. Shuffett said, “It is a distinct honor to be among the companies selected for a poster presentation at the Respiratory Innovation Summit.

MyPrize Emerges Out of Stealth With $140 Million Total Enterprise Value, the Most Valuable Online Social Casino Pre-Launch

Retrieved on: 
水曜日, 3月 27, 2024
Professional Services, Entertainment, Technology, Cryptocurrency, Internet, Casino, Gaming, CIO, Dragonfly, Friends, Entrepreneurship, FTX, General partnership, Kadoorie family, Galaxy Digital, Silicon, Jack Entertainment, XP, Justice, Former, Bruch, Multimedia, Blockchain.com

MyPrize transcends those boundaries, giving players and fans what they have been desperately craving: a unified, open platform that combines the best of both online gaming and streaming.

Key Points: 
  • MyPrize transcends those boundaries, giving players and fans what they have been desperately craving: a unified, open platform that combines the best of both online gaming and streaming.
  • MyPrize radically transforms the way players can interact and engage with their favorite streamers, friends, and online games together.
  • MyPrize brings scale and institutional credibility to this emerging industry as the most valuable venture-backed online social casino pre-launch.
  • "With the support of our investors and our team’s commitment to rapid product innovation, MyPrize will define the future of online social gaming."

Iron Senergy Responds to Senator Casey

Retrieved on: 
木曜日, 4月 4, 2024
Carbon, Lifting, Coal, Natural Resources, Risk, Iron, Justin Thompson, Politics, Appalachian Mountains, Coal mining, Life, EPA, Workforce, Retirement, Miner, Multimedia, Bob Casey Jr., Commonwealth, Renewable energy

Through his recent press releases, Senator Casey has made it clear that the continued operation of coal-producing assets, like the Cumberland Mine, is in the "best interest of our nation."

Key Points: 
  • Through his recent press releases, Senator Casey has made it clear that the continued operation of coal-producing assets, like the Cumberland Mine, is in the "best interest of our nation."
  • Senator Casey has made it clear that he will fight for the miners, families and economy of Greene County.
  • For that reason, I am inviting Senator Casey to visit our operations as soon as it can be arranged to discuss his support of the Cumberland Mine, which as Senator Casey notes, has been a large employer in Greene County since the 1970s.
  • Senator Casey speaks of the need for coal miners to be certain about their future.

Government of Canada announces funding for Nova Scotia community organization to implement mental health and grief supports for families

Retrieved on: 
火曜日, 4月 2, 2024
Community, Firearm, Addiction, Government, Mental health, Grief, Environment, The Honourable, MCC, Wellness

To support those affected on their paths to healing, the Government of Canada is investing in community-based solutions to help increase mental health, grief and bereavement services in Nova Scotia, as recommended by the Mass Casualty Commission.

Key Points: 
  • To support those affected on their paths to healing, the Government of Canada is investing in community-based solutions to help increase mental health, grief and bereavement services in Nova Scotia, as recommended by the Mass Casualty Commission.
  • This funding will help support the delivery of family-centred health promotion programs that address the unique needs of individuals and communities.
  • "The ongoing mental health impacts following the devastating loss of life in Nova Scotia in 2020 cannot be understated.
  • Anyone in Canada can visit Canada.ca/mental-health to access mental health and substance use supports and services, available both where they live and virtually.

RS BioTherapeutics Creates Therapeutic Expert Council to Provide Guidance on Development of First-in-Class Agent Focused on Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis

Retrieved on: 
水曜日, 2月 21, 2024
TEC, IPF, University, Idiopathic disease, Division, Assistant, Critical care, Idiopathic pulmonary fibrosis, Chronic obstructive pulmonary disease, Clinical research, Outline of health sciences, Consultant, Respiratory Medicine, Death, SUNY, Observation, Harvard Medical School, COPD, Pharmaceutical industry

CUMBERLAND, Md., Feb. 21, 2024 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to develop life-changing medicines for the millions of people suffering from diseases characterized by pulmonary inflammation, is pleased to announce the formation of its Therapeutic Expert Council (TEC).

Key Points: 
  • CUMBERLAND, Md., Feb. 21, 2024 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to develop life-changing medicines for the millions of people suffering from diseases characterized by pulmonary inflammation, is pleased to announce the formation of its Therapeutic Expert Council (TEC).
  • The TEC will help guide the development of RS BioTherapeutics’ first-in-class, steroid-free agent, RSBT-001, in development for Chronic Obstructive Pulmonary Disease (COPD), the third leading cause of death in the world; and Idiopathic Pulmonary Fibrosis (IPF), a rare disease with no cure that claims 40,000 lives each year in the U.S.
  • All have exceptional credentials and are uniquely qualified to help support the development of our first investigational compound, RSBT-001.
  • I’m excited to collaborate with them and look forward to engaging their diverse perspectives spanning the fields of COPD, IPF, and other diseases characterized by pulmonary inflammation.”

Cumberland Trust Appoints David Murray as Managing Director, Corporate Development, as Company Reaches $8 Billion in Assets Under Administration

Retrieved on: 
火曜日, 3月 5, 2024
Finance, Consulting, Banking, Professional Services, Asset Management, Diamond, Multimedia, Education, Civil engineering, University, Strategic planning, Corporate development, Trust, Property management

Cumberland Trust, a Nashville-based independent trust company, announces the addition of David Murray to its Corporate Development team as Managing Director.

Key Points: 
  • Cumberland Trust, a Nashville-based independent trust company, announces the addition of David Murray to its Corporate Development team as Managing Director.
  • View the full release here: https://www.businesswire.com/news/home/20240305877178/en/
    With more than 20 years of industry experience, Murray brings considerable expertise in personal trust and estate planning to the growing Cumberland Trust team.
  • “As an expert and trusted advisor in the wealth management industry, we are thrilled to add Dave to our Corporate Development leadership team,” said Jennie Menzie, CEO and President of Cumberland Trust.
  • As a frequent speaker for trust, estate, and wealth industry events, Murray brings trust solutions to professional audiences through education.

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2023 FINANCIAL RESULTS

Retrieved on: 
火曜日, 2月 27, 2024
Fever, Ibuprofen, Clarithromycin, PIN, Lactulose, Multimedia, FDA, Acetylcysteine, Pain, Omeprazole, Granisetron, Amoxicillin, Idiopathic pulmonary fibrosis, Skin, Nausea, Vomiting, Constipation, Duchenne muscular dystrophy, Cardiomyopathy, Fungal infection, Hyponatremia, Paracetamol, Health, Patient, Helicobacter pylori, Infection, Gastroenterology

NASHVILLE, Tenn., Feb. 27, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release its annual 2023 financial results and provide a company update after the market closes on Tuesday, March 5, 2024.

Key Points: 
  • NASHVILLE, Tenn., Feb. 27, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release its annual 2023 financial results and provide a company update after the market closes on Tuesday, March 5, 2024.
  • A conference call will be held on March 5 at 4:30 p.m. Eastern Time to discuss the results.
  • Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them.
  • Alternatively, they can choose a "Call Me" option to have the system automatically call them at the start of the conference.

RS BioTherapeutics Promotes Michelle L. Shuffett, MD to Chief Medical Officer

Retrieved on: 
火曜日, 10月 31, 2023
Knowledge, University, Children's Hospital Los Angeles, London, Medicine, Barts and The London School of Medicine and Dentistry, Born This Way Foundation, MD, TEC, Bureau of Oceans and International Environmental and Scientific Affairs, Organization, Health, Research, IPF, Senior, RS, Boehringer Ingelheim, Everyday Health, Idiopathic disease, UCLA Mattel Children's Hospital, NIH, Patient, Hospital, COPD, Idiopathic pulmonary fibrosis, Child, Pharmaceutical industry, Nursing, Economics

CUMBERLAND, Md., Oct. 31, 2023 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to develop life-changing medicines for the millions of people suffering from diseases characterized by pulmonary inflammation, is pleased to announce that it has appointed Michelle L. Shuffett, MD as its Chief Medical Officer.

Key Points: 
  • CUMBERLAND, Md., Oct. 31, 2023 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to develop life-changing medicines for the millions of people suffering from diseases characterized by pulmonary inflammation, is pleased to announce that it has appointed Michelle L. Shuffett, MD as its Chief Medical Officer.
  • Commenting on the promotion of Dr. Shuffett to Chief Medical Officer, Dean Hart, Chief Executive Officer of RS BioTherapeutics said, “Michelle has been a tremendous addition to our leadership team.
  • Michelle will Chair the TEC and that group will help guide the development of RSBT-001.”
    Commenting on her appointment, Dr. Shuffett said, “I’m thrilled to continue working with the incredible leadership team at RS BioTherapeutics in this new role.
  • Dr. Shuffett has also served in senior roles at several organizations including Synapse Medical Communications, Everyday Health, Columbia Care, and Radicle Science.